HLN Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of 17.45% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 5.94% beat Biodexa Pharmaceuticals PLC's return on equity of --.

Haleon PLC has a consensus price target of --, signalling upside risk potential of 10.65%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 109.82%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Haleon PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.62%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 36.99% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.6B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Haleon PLC's net income of $631.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 28.73x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.13x versus 3.44x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

GSK PLC has a net margin of 17.45% compared to Haleon PLC's net margin of -0.72%. Haleon PLC's return on equity of 5.94% beat GSK PLC's return on equity of 18.89%.

Haleon PLC has a consensus price target of --, signalling upside risk potential of 10.65%. On the other hand GSK PLC has an analysts' consensus of $42.93 which suggests that it could grow by 32.34%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.349%.

Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.62%. GSK PLC offers a yield of 4.59% to investors and pays a quarterly dividend of $0.39 per share. Haleon PLC pays 36.99% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.6B, which are smaller than GSK PLC quarterly revenues of $10.4B. Haleon PLC's net income of $631.1M is higher than GSK PLC's net income of -$75.5M. Notably, Haleon PLC's price-to-earnings ratio is 28.73x while GSK PLC's PE ratio is 22.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.13x versus 1.77x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 17.45% compared to Haleon PLC's net margin of 25.23%. Haleon PLC's return on equity of 5.94% beat Pfizer's return on equity of 4.63%.

Haleon PLC has a consensus price target of --, signalling upside risk potential of 10.65%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that Pfizer has higher upside potential than Haleon PLC, analysts believe Pfizer is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.62%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Haleon PLC pays 36.99% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Haleon PLC quarterly revenues are $3.6B, which are smaller than Pfizer quarterly revenues of $17.7B. Haleon PLC's net income of $631.1M is lower than Pfizer's net income of $4.5B. Notably, Haleon PLC's price-to-earnings ratio is 28.73x while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.13x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Smith & Nephew PLC has a net margin of 17.45% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 5.94% beat Smith & Nephew PLC's return on equity of 5.85%.

Haleon PLC has a consensus price target of --, signalling upside risk potential of 10.65%. On the other hand Smith & Nephew PLC has an analysts' consensus of $35.35 which suggests that it could grow by 32.66%. Given that Smith & Nephew PLC has higher upside potential than Haleon PLC, analysts believe Smith & Nephew PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Smith & Nephew PLC has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.545%.

Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.62%. Smith & Nephew PLC offers a yield of 3.06% to investors and pays a quarterly dividend of $0.29 per share. Haleon PLC pays 36.99% of its earnings as a dividend. Smith & Nephew PLC pays out 124.34% of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Smith & Nephew PLC's is not.

Haleon PLC quarterly revenues are $3.6B, which are larger than Smith & Nephew PLC quarterly revenues of --. Haleon PLC's net income of $631.1M is higher than Smith & Nephew PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 28.73x while Smith & Nephew PLC's PE ratio is 35.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.13x versus 1.90x for Smith & Nephew PLC. Usually stocks with elevated PS ratios are considered overvalued.